Latest from Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute

Edwin M. Posadas, MD, FACP, discusses recent prostate cancer data and sheds light on where emerging therapies may fit into this landscape.
Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses the future of treatment for patients with renal cell carcinoma.
Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses considerations when combining TKIs and immunotherapy agents in the management of advanced renal cell carcinoma.
Using wearable activity monitors may eventually supplement standard assessments of performance status and functionality that could inform clinicians, especially because objective evaluation of performance status is difficult to determine.
Timothy J. Daskivich, MD, assistant professor of surgery, Cedars-Sinai Medical Center, discusses the future treatment landscape of prostate cancer.
Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor of medicine, Cedars-Sinai Medical Center, discusses unmet needs in prostate cancer.
Hyung L. Kim, MD, Medallion Group Chair in Urology, co-medical director of the Urologic Oncology Center, associate director, Surgical Research in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses the potential combination of immunotherapy and tyrosine kinase inhibitors in metastatic renal cell carcinoma.
Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the future of kidney cancer treatment.
Publication Bottom Border
Border Publication
x